CTI BioPharma Corp.
CTIC•NASDAQ
CTI BioPharma Corp.
CTIC•NASDAQ
Sentiment
Phase 1 · Company Overview
Step 1: Overview
What the company does, where it operates, and who runs it.
Overview for CTI BioPharma Corp.
Industry:Biotechnology
Sector:Healthcare
CEO:Adam R. Craig
Description:CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Address:N/A
Step 2: Infographics
Visual summary of the business at a glance.
Phase 2 · FRC Research
Step 3: Media
Videos and interviews covering the company.
Phase 3 · Financial Data
Step 4: Stock Data
Price chart, volume, and trading data.
CTIC Stock Price
Step 5: Fair Value
What FRC thinks the stock is worth vs. the current price.
Step 6: Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Step 7: Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Step 8: Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Step 9: Financial Statements
Income statement, balance sheet, and cash flow statements.
Phase 4 · Peer Comparison
Step 10: Comparables
List of peer companies in the same industry.
Phase 5 · Ownership & News
Step 12: Institutional Ownership
Which funds and firms own the stock.
Step 13: Insider Trading
Recent buying and selling by company executives.
Step 14: Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
Step 15: News
Latest headlines and market coverage.
News
Latest Market News